Veozah evaluation for menopause symptoms in NYC

Veozah is fezolinetant, a nonhormonal oral medicine for moderate to severe menopause-related hot flashes and night sweats. It is not estrogen. The February 2026 US label has a boxed hepatotoxicity warning and a defined liver-monitoring schedule. The label uses a 45 mg tablet orally once daily with or without food, swallowed whole. Before starting, complete safety tests and arrange follow-up testing and refills. Compare choices with the clinician; do not switch between Veozah and Lynkuet using a shared dosing or monitoring schedule.

Fezolinetant blocks neurokinin 3 receptors involved in the temperature-regulation pathway affected by menopause. It treats vasomotor symptoms rather than replacing ovarian hormones or treating vaginal infection. Its safety requirements differ from Lynkuet and hormone therapy.

Obtain baseline ALT, AST, alkaline phosphatase and total and direct bilirubin. Do not start if ALT or AST, or total bilirubin, is at least twice the upper limit of normal. Bring every medicine and supplement for interaction review and establish where scheduled labs will be obtained.

The clinician reviews vasomotor symptoms, liver and kidney disease and the full medicine list. Veozah is contraindicated with known cirrhosis, severe renal impairment or end-stage renal disease, and CYP1A2 inhibitors. Clinical suitability does not follow solely from a preference to avoid hormones.

Both are nonhormonal treatments for menopause-related vasomotor symptoms. Lynkuet blocks NK1/NK3, is taken at bedtime and needs baseline and three-month liver review plus sleepiness and seizure precautions. Veozah blocks NK3 and has a boxed liver warning with tests monthly for three months, then at six and nine months. They have different interactions and contraindications.

Stop Veozah and seek medical attention promptly for possible liver injury, including new marked fatigue, nausea, vomiting, itching, jaundice, pale stools, dark urine or abdominal pain. The clinician obtains liver tests and decides next steps. Do not wait for the next scheduled laboratory date when symptoms occur.

Coverage depends on the exact service, product, indication, provider and plan rules. Confirm the clinician and pharmacy route before starting. Visit coverage does not guarantee medication coverage, and manufacturer support or a sample does not guarantee affordable refills. Ask about authorization, testing, costs and follow-up. Confirm whether the selected clinic prescribes the product and whether the pharmacy can fill the exact dose.

Confirm the exact service at the selected clinic before booking. Evaluation, prescribing, testing, training and administration are separate capabilities. Confirm the clinician and pharmacy route before starting. Visit coverage does not guarantee medication coverage, and manufacturer support or a sample does not guarantee affordable refills. Ask about authorization, testing, costs and follow-up. Confirm whether the selected clinic prescribes the product and whether the pharmacy can fill the exact dose.

Before treatment starts, confirm the diagnosis, the intended benefit, the exact treatment and who will coordinate ongoing care. The label uses a 45 mg tablet orally once daily with or without food, swallowed whole. Before starting, complete safety tests and arrange follow-up testing and refills. Compare choices with the clinician; do not switch between Veozah and Lynkuet using a shared dosing or monitoring schedule.

Prepare the relevant dated records, current medicine list and your main questions, and confirm any treatment-specific instructions before attending. Obtain baseline ALT, AST, alkaline phosphatase and total and direct bilirubin. Do not start if ALT or AST, or total bilirubin, is at least twice the upper limit of normal. Bring every medicine and supplement for interaction review and establish where scheduled labs will be obtained.

Agree on the next review, how response and safety will be checked, and who to contact for symptoms, missed treatment or a refill problem. Follow-up liver tests are required monthly for the first three months, then at six and nine months after starting. Review symptom benefit and tolerability too. Continued symptom improvement does not remove monitoring requirements. Persistent or new symptoms need assessment rather than an automatic dose increase.

Weight gain is not listed among the common adverse reactions in the current US label. That does not rule out an individual reaction or explain a new change. Discuss the amount and timing, other medicines and symptoms with the clinician. Continue required liver testing even if hot flashes improve. Stop Veozah and seek medical attention promptly for possible liver injury, such as jaundice, dark urine, pale stools, marked fatigue or abdominal pain; do not wait for a weight-focused follow-up if these occur.

Hair loss is not among the common adverse reactions listed in the current US label. That does not prove it cannot occur or that another cause is certain. Report new shedding, scalp changes and the timing to the prescriber, who can review other medicines and health changes. Do not increase the dose or switch menopause medicines yourself. Veozah’s required liver tests still apply: monthly for the first three months, then at months six and nine, even when symptoms improve.

No. Veozah is fezolinetant, a neurokinin 3 receptor antagonist approved for moderate-to-severe menopause-related hot flashes. It is a nonhormonal medicine and is not an SSRI, SNRI or estrogen treatment. That classification does not establish that it treats depression or is suitable without safety checks. Review liver and kidney disease and interacting medicines with the prescriber, and arrange the required baseline and follow-up liver tests.

The pivotal trials assessed hot-flash frequency and severity at weeks 4 and 12 and found average improvement compared with placebo. Those study dates do not predict the first day you will notice benefit or guarantee that every symptom will resolve. Track hot flashes and night sweats and review the response with the prescriber rather than changing the dose. Liver safety remains separate from symptom benefit: complete baseline testing, monthly tests for the first three months, then tests at months six and nine. Possible liver-injury symptoms require stopping the medicine and prompt medical attention.

Ask the dispensing pharmacy for its current cash price for the prescribed 45-mg daily supply. A list price, advertisement or another patient’s payment is not a confirmed quote for your prescription. Ask separately about the evaluation and required liver tests, since those are not included in every medicine quote. If you have insurance, verify the formulary, authorization and cost sharing; savings-program eligibility is a separate decision. Confirm the ongoing refill and testing cost before starting, because monitoring cannot be skipped to lower the bill.